Thrombosis - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 156 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Thrombosis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Thrombosis - Pipeline Review, H2 2014', provides an overview of the Thrombosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Thrombosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Thrombosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Thrombosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Thrombosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Thrombosis Overview 8
Therapeutics Development 9
Pipeline Products for Thrombosis - Overview 9
Pipeline Products for Thrombosis - Comparative Analysis 10
Thrombosis - Therapeutics under Development by Companies 11
Thrombosis - Therapeutics under Investigation by Universities/Institutes 14
Thrombosis - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Thrombosis - Products under Development by Companies 21
Thrombosis - Products under Investigation by Universities/Institutes 24
Thrombosis - Companies Involved in Therapeutics Development 26
Archemix Corp. 26
Astellas Pharma Inc. 27
AstraZeneca PLC 28
Bristol-Myers Squibb Company 29
Cardax Pharmaceuticals, Inc. 30
CSL Limited 31
Daewoong Pharmaceutical Co., Ltd. 32
IMMD Inc. 33
Isis Pharmaceuticals, Inc. 34
LG Life Sciences, Ltd. 35
Lipicard Technologies Limited 36
Medicure Inc. 37
Merck & Co., Inc. 38
MSM Protein Technologies, Inc. 39
Nostrum Pharmaceuticals, LLC 40
Pfizer Inc. 41
PLx Pharma Inc. 42
Portola Pharmaceuticals, Inc. 43
Sagene Pharmaceuticals, Inc. 44
SciFluor Life Sciences, LLC 45
Zedira GmbH 46
Thrombosis - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Target 49
Assessment by Mechanism of Action 52
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 58
ANV-6L15 - Drug Profile 58
ARC-15105 - Drug Profile 59
ASP-6537 - Drug Profile 60
aspirin - Drug Profile 62
BMS-262084 - Drug Profile 64
BMS-816106 - Drug Profile 65
BMS-884775 - Drug Profile 66
CDX-085 - Drug Profile 67
CLB-100 - Drug Profile 69
CSL-3F7 - Drug Profile 70
DD-2 - Drug Profile 71
Drug for Thrombosis - Drug Profile 72
Drug to Activate Endothelial Protein C Receptor for Inflammation and Thrombosis - Drug Profile 73
Drugs for Thrombosis - Drug Profile 74
DWJ-1261 - Drug Profile 75
DWJ-1355 - Drug Profile 76
IMD-4852 - Drug Profile 77
Ir-CPI - Drug Profile 78
ISIS-FVIIRx - Drug Profile 79
LC-231306 - Drug Profile 80
LT-5121 - Drug Profile 81
LT-5122 - Drug Profile 82
LT-5521 - Drug Profile 83
MC-45301 - Drug Profile 84
MC-45308 - Drug Profile 85
MC-45350 - Drug Profile 86
MC-45403 - Drug Profile 87
Monoclonal Antibodes to Activate TREM-like transcript-1 Receptor for Thrombosis and Hemostasis - Drug Profile 88
MSM-236 - Drug Profile 89
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 90
Peptides for Immunology and Cardiovascular Disorders - Drug Profile 91
PF-00190434 - Drug Profile 92
PRT-060318 - Drug Profile 93
Recombinant Protein for Thrombosis and Non-Small Cell Lung Cancer - Drug Profile 94
Recombinant Protein for Thrombosis and Stroke - Drug Profile 95
Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile 96
rGPG-290 - Drug Profile 97
S-002333 - Drug Profile 98
S-007867 - Drug Profile 99
selegiline + Antiplatelet Drugs - Drug Profile 100
Small Molecule for Thrombosis - Drug Profile 101
Small Molecule for Thrombosis - Drug Profile 102
Small Molecule to Antagonize P2Y12 for Thrombosis - Drug Profile 103
Small Molecule to Inhibit ASK1 for Thrombosis - Drug Profile 104
Small Molecule to Inhibit Factor XIa for Thrombosis - Drug Profile 105
Small Molecule To inhibit PAR-1 for Atherothrombosis - Drug Profile 106
Small Molecules for Hematological Disorders and Cancer - Drug Profile 107
Small Molecules for Thrombosis - Drug Profile 108
Small Molecules for Thrombosis and Stroke - Drug Profile 109
Small Molecules to Inhibit Carboxypeptidase U for Thrombosis - Drug Profile 110
Small Molecules to Inhibit Factor XIII for Thrombosis - Drug Profile 111
Small Molecules to Inhibit P2Y12 Receptor for Thrombosis - Drug Profile 112
Small Molecules to Inhibit PDI for Thrombosis - Drug Profile 113
Small Molecules to Inhibit Purinergic Receptor for Thrombosis - Drug Profile 114
Small Molecules to Inhibit Thrombin for Thrombosis and Oncology - Drug Profile 115
Small Molecules to Inhibit TNF-a for Cardiovascular and CNS Disorders - Drug Profile 116
SMRX-11 - Drug Profile 117
Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury - Drug Profile 118
Synthetic Peptides to Inhibit Glycoprotein VI for Thrombosis - Drug Profile 119
Tanshinone IIA - Drug Profile 120
TM-5275 - Drug Profile 121
TM-5509 - Drug Profile 122
TTS-01 - Drug Profile 123
UM-8190 - Drug Profile 124
vorapaxar sulfate - Drug Profile 125
Thrombosis - Recent Pipeline Updates 127
Thrombosis - Dormant Projects 130
Thrombosis - Discontinued Products 135
Thrombosis - Product Development Milestones 137
Featured News & Press Releases 137
Appendix 150
Methodology 150
Coverage 150
Secondary Research 150
Primary Research 150
Expert Panel Validation 150
Contact Us 151
Disclaimer 151

List of Tables
Number of Products under Development for Thrombosis, H2 2014 14
Number of Products under Development for Thrombosis - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 17
Number of Products under Development by Companies, H2 2014 (Contd..1) 18
Number of Products under Investigation by Universities/Institutes, H2 2014 20
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 21
Comparative Analysis by Late Stage Development, H2 2014 22
Comparative Analysis by Clinical Stage Development, H2 2014 23
Comparative Analysis by Early Stage Development, H2 2014 24
Comparative Analysis by Unknown Stage Development, H2 2014 25
Products under Development by Companies, H2 2014 26
Products under Development by Companies, H2 2014 (Contd..1) 27
Products under Development by Companies, H2 2014 (Contd..2) 28
Products under Investigation by Universities/Institutes, H2 2014 29
Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 30
Thrombosis - Pipeline by Archemix Corp., H2 2014 31
Thrombosis - Pipeline by Astellas Pharma Inc., H2 2014 32
Thrombosis - Pipeline by AstraZeneca PLC, H2 2014 33
Thrombosis - Pipeline by Bristol-Myers Squibb Company, H2 2014 34
Thrombosis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2014 35
Thrombosis - Pipeline by CSL Limited, H2 2014 36
Thrombosis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2014 37
Thrombosis - Pipeline by IMMD Inc., H2 2014 38
Thrombosis - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 39
Thrombosis - Pipeline by LG Life Sciences, Ltd., H2 2014 40
Thrombosis - Pipeline by Lipicard Technologies Limited, H2 2014 41
Thrombosis - Pipeline by Medicure Inc., H2 2014 42
Thrombosis - Pipeline by Merck & Co., Inc., H2 2014 43
Thrombosis - Pipeline by MSM Protein Technologies, Inc., H2 2014 44
Thrombosis - Pipeline by Nostrum Pharmaceuticals, LLC, H2 2014 45
Thrombosis - Pipeline by Pfizer Inc., H2 2014 46
Thrombosis - Pipeline by PLx Pharma Inc., H2 2014 47
Thrombosis - Pipeline by Portola Pharmaceuticals, Inc., H2 2014 48
Thrombosis - Pipeline by Sagene Pharmaceuticals, Inc., H2 2014 49
Thrombosis - Pipeline by SciFluor Life Sciences, LLC, H2 2014 50
Thrombosis - Pipeline by Zedira GmbH, H2 2014 51
Assessment by Monotherapy Products, H2 2014 52
Assessment by Combination Products, H2 2014 53
Number of Products by Stage and Target, H2 2014 55
Number of Products by Stage and Mechanism of Action, H2 2014 58
Number of Products by Stage and Route of Administration, H2 2014 60
Number of Products by Stage and Molecule Type, H2 2014 62
Thrombosis Therapeutics - Recent Pipeline Updates, H2 2014 132
Thrombosis - Dormant Projects, H2 2014 135
Thrombosis - Dormant Projects (Contd..1), H2 2014 136
Thrombosis - Dormant Projects (Contd..2), H2 2014 137
Thrombosis - Dormant Projects (Contd..3), H2 2014 138
Thrombosis - Dormant Projects (Contd..4), H2 2014 139
Thrombosis - Discontinued Products, H2 2014 140
Thrombosis - Discontinued Products (Contd..1), H2 2014 141